Cover Image
市場調查報告書

OpportunityAnalyzer:難辨梭狀芽孢桿菌傳染病 (CDI) 的市場機會分析及預測

OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024

出版商 GlobalData 商品編碼 349763
出版日期 內容資訊 英文 322 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:難辨梭狀芽孢桿菌傳染病 (CDI) 的市場機會分析及預測 OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
出版日期: 2015年10月09日 內容資訊: 英文 322 Pages
簡介

全球主要7個國家難辨梭狀芽孢桿菌傳染病 (CDI) 的預防藥及治療藥市場,預測從2014年約3億5600萬美元以15.8%的年複合成長率成長,到2024年成長超過15億美元的規模。該市場的成長,預測將受到加入標準治療的抗生素之新輔助療法的引進擴大和Merck的抗生劑Dificid利用的擴大,Sanofi Pasteur的全球最初預防疫苗ACAM-CDIFF的興起等因素所推動。

本報告調查難辨梭狀芽孢桿菌傳染病 (CDI) 的治療藥·預防藥市場,提供您疾病及疾病管理概要,全球主要7個國家發病情形,目前治療藥,未滿足需求與市場機會分析,R&D策略,開發平台的主要藥物趨勢,開發平台藥物的基準·競爭分析,彙整主要7個國家市場上治療藥·預防藥的銷售額預測等資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 風險因素·症狀
  • 疾病管理
    • 診斷
    • 治療指南
    • 臨床診療
    • 預防·管理
  • 預後·QoL

第4章 流行病學

  • 疾病背景
  • 風險因素·並存症
  • 全球趨勢
    • 主要7個國家市場:發病診斷率
    • 主要7個國家市場:發病診斷數與免疫學的因果關係
    • 主要7個國家市場:發病診斷數與復發數
  • 預測手法
  • CDI的流行病學的預測
    • 發病診斷數
    • 發病診斷數:各年齡
    • 發病診斷數:男女
    • 發病診斷率:年齡水平化
    • 復發數
    • 發病診斷數與免疫學的因果關係
  • 討論
    • 流行病學的預測相關考察
    • 預測的規定
    • 預測的優勢

第5章 目前治療藥

  • 概要
  • 產品簡介:推薦抗生素治療
    • Metronidazole
    • Vancomycin
    • Dificid (fidaxomicin)
  • 其他抗生素治療
    • Targocid (teicoplanin)
    • Tygacil (tigecycline)
    • Xifaxan (rifaximin)
  • 其他藥劑治療
    • 免疫療法
  • 非藥物的治療
    • FTM (航班微生物移植)
    • 益生菌
    • 外科手術

第6章 未滿足需求的評估·市場機會分析

  • 概要
  • 改善復發CDI的治療選擇
  • CDI預防產品
  • FMT的長期安全性的標準化·合理化·確認
  • 降低重病併發性CDI患者的盛行率·死亡率的產品
  • 被臨床性證明的CDI風險標準·預測模式
  • 改善感染·流行的監視及迴避策略
    • 未滿足需求
    • 差距分析
    • 市場機會

第7章 R&D策略

  • 概要
  • CDI產品開發的目前方法
    • 抗生素
    • 非抗純粹補助藥
    • 非抗純粹預防
    • 疫苗
  • 臨床試驗設計
    • 治療產品
    • 預防產品
  • 未來臨床開發相關考察

第8章 開發平台的評估

  • 概要
  • 臨床開發確實的產品
  • 治療藥:生物製藥·免疫治療藥
    • Actoxumab·Bezlotoxumab
  • 治療藥:抗生素
    • Cadazolid
    • Surotomycin
    • SMT19969
  • 治療藥:微生物
    • SER-109
    • RBX2660
  • 預防藥:疫苗
    • ACAM-CDIFF
    • VLA84
    • PF-06425090
  • CDI預防·治療的其他創新產品·方法
    • LFF571
    • Ramoplanin
    • VP20621
    • SYN-004
  • 正在開發的其他CDI產品

第9章 開發平台的評估·分析

  • 主要開發中產品的臨床性基準
    • 治療產品
    • 預防產品
  • 主要開發中產品的商業性基準
    • 治療產品
    • 預防產品
  • 競爭評估
    • 治療產品
    • 預防產品
  • top line10年預測
    • 美國
    • 歐盟5國
    • 日本

第10章 附錄

圖表

目錄
Product Code: GDHC037POA

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD). CDI onset begins with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. C. difficile has been identified as a major cause of antibiotic-associated pseudomembranous colitis and diarrhea, with the earliest cases largely attributed to clindamycin. As penicillins and cephalosporins became more widely used throughout the years, their administration also became associated with an increased risk of developing CDAD. Since 2000, CDIs have become more frequent, more severe, more difficult to treat using existing therapies, and more likely to recur than previously described. These realities, along with increasing threat of antibiotic resistance, underscore the importance of developing CDI-specific therapies and bringing them to market.

For the purposes of this report, GlobalData defines the global CDI market to include sales of therapeutic and prophylactic agents aimed at treatment and prevention of CDI and CDAD in patients 18 years and older across the 7MM, which is comprised of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData anticipates a major driver of market growth to be the steady increase in uptake of novel CDI-specific antibiotics once they are approved, but the arrival of non-antibiotic products to the market, such as rationally designed microbiologics and vaccines, are poised to make the biggest clinical impact if approved.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the CDI marketplace. Will the leading therapeutic and prophylactic pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?
  • What research and development (R&D) strategies will companies leverage to compete in the future CDI marketplace?
  • What adjunctive therapies to standard of care (SOC) antibiotics are poised to make a major clinical and commercial impact?
  • What clinical and commercial factors are likely to influence CDI product uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK) and Japan (7MM)?

Key Findings

  • GlobalData projects CDI therapeutics and prophylactics market in the 7MM to grow from approximately $356m in 2014 to a little over $1.5bn in 2024, at a compound annual growth rate (CAGR) of 15.8%. This growth will be driven by the increased uptake of novel adjunctive therapies to SOC antibiotics, increased use of Merck's first-to-market antibiotic Dificid, and the arrival of ACAM-CDIFF, the world's first prophylactic vaccine developed by Sanofi Pasteur to prevent primary infections.
  • KOLs interviewed by GlobalData were split on the ability of a prophylactic vaccine developer to demonstrate statistically significant prevention of primary infections in a pivotal Phase III study, specifically citing difficulties reliably anticipating CDI transmission in the patient population. Expert consensus was that non-antibiotic approaches, specifically rationally designed microbiologic therapies, have the potential to shift the treatment paradigm for intractable recurrent infections, although antibiotics should remain the main treatment options through 2024.
  • GlobalData anticipates that firms will continue to invest in CDI-specific antibiotics development throughout the forecast period, but product differentiation will remain a difficult task due to the high clinical cure rates with current cost-effective generic antibacterials and the superior sustained cure rate exhibited with Merck's Dificid.

Scope

  • Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Topline CDI therapeutics and prophylactics market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, and R&D strategies for the CDI market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global CDI market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global CDI therapeutic and prophylactic markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Risk Factors and Symptoms
  • 3.3. Disease Management
    • 3.3.1. Diagnosis
    • 3.3.2. Treatment Guidelines
    • 3.3.3. Clinical Practice
    • 3.3.4. Prevention and Control
  • 3.4. Prognosis and Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. 7MM: Diagnosed Incidence Rates
    • 4.3.2. 7MM: Diagnosed Incident Cases by Epidemiological Association
    • 4.3.3. 7MM: Diagnosed Incident Cases by Recurrence
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of CDI (2014-2024)
    • 4.5.1. Diagnosed Incident Cases of All-CDI
    • 4.5.2. Age-Specific Diagnosed Incident Cases of All-CDI
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of All-CDI
    • 4.5.4. Age-Standardized Diagnosed Incidence Rate of All-CDI
    • 4.5.5. Recurrent CDI Cases
    • 4.5.6. Diagnosed Incident Cases of All-CDI by Epidemiological Association
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
  • 5.2. Product Profiles - Recommended Antibiotic Therapies
    • 5.2.1. Metronidazole
    • 5.2.2. Vancomycin
    • 5.2.3. Dificid (fidaxomicin)
  • 5.3. Other Antibiotic Therapies
    • 5.3.1. Targocid (teicoplanin)
    • 5.3.2. Tygacil (tigecycline)
    • 5.3.3. Xifaxan (rifaximin)
  • 5.4. Other Drug Interventions
    • 5.4.1. Immunotherapy
  • 5.5. Non-Drug Interventions
    • 5.5.1. Fecal Microbiota Transplant
    • 5.5.2. Probiotics
    • 5.5.3. Surgical Procedures

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Improved Treatment Options for Recurrent CDI
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Prophylactic Products to Prevent CDI
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Standardize, Streamline, and Confirm Long-Term Safety of FMT
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Products to Reduce Morbidity and Mortality in Patients with Severe-Complicated CDI
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Clinically Proven CDI Risk Criteria and Prediction Models
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improve Surveillance and Prevent Transmission and Outbreaks
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Research and Development Strategies

  • 7.1. Overview
  • 7.2. Current Approaches to CDI Product Development
    • 7.2.1. Antibiotics
    • 7.2.2. Non-Antibiotic Adjunctive Therapeutics
    • 7.2.3. Non-Antibiotic Prophylactic Agents
    • 7.2.4. Vaccines
  • 7.3. Clinical Trial Design
    • 7.3.1. Therapeutic Agents
    • 7.3.2. Prophylactic Agents
  • 7.4. Special Considerations for Future Clinical Development
    • 7.4.1. Patient Selection in Late-Stage Efficacy Studies for Prophylactic Products
    • 7.4.2. Active Comparators and Superiority Trial Designs for New CDI-Specific Antibiotics
    • 7.4.3. Rationally Designed Microbiologics Need to Show Superior Safety Profiles Compared to FMT

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Products in Clinical Development
  • 8.3. Therapeutic Agents - Biologics and Immunotherapies
    • 8.3.1. Actoxumab and Bezlotoxumab (anti-C. difficile toxins A and B)
  • 8.4. Therapeutic Agents - Antibiotics
    • 8.4.1. Cadazolid
    • 8.4.2. Surotomycin
    • 8.4.3. SMT19969
  • 8.5. Therapeutic Agents - Microbiologics
    • 8.5.1. SER-109 (firmacute eubacterial spores, purified suspensions, encapsulated)
    • 8.5.2. RBX2660 (microbiota suspension)
  • 8.6. Prophylactic Agents - Vaccines
    • 8.6.1. ACAM-CDIFF
    • 8.6.2. VLA84
    • 8.6.3. PF-06425090
  • 8.7. Other Innovative Products and Approaches to CDI Prevention and Treatment
    • 8.7.1. LFF571
    • 8.7.2. Ramoplanin
    • 8.7.3. VP20621 (non-toxigenic C. difficile strain M3 spores)
    • 8.7.4. SYN-004
  • 8.8. Other CDI Products in Development

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Products
    • 9.1.1. Therapeutic Agents
    • 9.1.2. Prophylactic Agents
  • 9.2. Commercial Benchmark of Key Pipeline Products
    • 9.2.1. Therapeutic Agents
    • 9.2.2. Prophylactic Agents
  • 9.3. Competitive Assessment
    • 9.3.1. Therapeutic Agents
    • 9.3.2. Prophylactic Agents
  • 9.4. Top-Line 10-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. CDI Patient Population Segmentation
    • 10.4.2. Percent Product-Treated Patients
    • 10.4.3. Products Included in Each Therapeutic Class
    • 10.4.4. Pipeline Product Projected Launch Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Product Assumptions
    • 10.4.7. Pricing of Pipeline Products
  • 10.5. Primary Research
    • 10.5.1. Physicians and Specialists Included in this Study
    • 10.5.2. Online Survey of High-Prescribing Physicians
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Epidemiologist
    • 10.6.3. Therapy Area Director
    • 10.6.4. Global Director of Therapy Analysis and Epidemiology
    • 10.6.5. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Antimicrobial Agents that May Induce CDI, CDAD, and Colitis
  • Table 2: Physiological Effects of C. difficile Toxins A and B
  • Table 3: Risk Factors Associated with CDI and CDAD
  • Table 4: Clinical Variants of CDI and Associated Symptoms
  • Table 5: Summary of Stool Laboratory Diagnostic Testing for C. difficile
  • Table 6: CDI Severity Scoring System and Summary of Recommended Treatments
  • Table 7: Risk Factors and Comorbidities for CDI
  • Table 8: Definitions of CDI Segmentations
  • Table 9: 7MM, Sources of CDI Diagnosed Incidence Data
  • Table 10: 7MM, Sources of CDI Recurrence Rates
  • Table 11: 7MM, Sources of CDI Epidemiological Association
  • Table 12: 7MM, Sources Not Used in Epidemiological Analysis of CDI
  • Table 13: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 14: 7MM, Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014.
  • Table 15: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014
  • Table 16: Product Profile - Metronidazole
  • Table 17: Adverse Reactions Reported During Treatment with Metronidazole
  • Table 18: Metronidazole SWOT Analysis, 2015
  • Table 19: Product Profile - Vancomycin
  • Table 20: Clinical Success of Vancomycin-Treated Subjects in Two Clinical Trials
  • Table 21: Common Adverse Reactions for Vancomycin in Treating CDAD*
  • Table 22: Vancomycin SWOT Analysis, 2015
  • Table 23: Product Profile - Dificid
  • Table 24: Dificid Pivotal Phase III Clinical Trials Response Rates
  • Table 25: Dificid Pivotal Phase III Clinical Trials Sustained Clinical Response at 25 Days After Treatment According to C. difficile Strain
  • Table 26: Selected Adverse Reactions with an Incidence of ≥2% Reported in Patients Treated with Dificid in Controlled Trials
  • Table 27: Dificid SWOT Analysis, 2015
  • Table 28: Unmet Need and Opportunity in Clostridium difficile Infections
  • Table 29: Key Products in the CDI Market by Therapeutic Class, 2015
  • Table 30: Clinical Trial Designs for CDI Pipeline Therapeutic Agents
  • Table 31: Clinical Trial Designs for CDI Pipeline Prophylactic Agents
  • Table 32: Promising Products in Clinical Development for CDIs, 2015
  • Table 33: Product Profile - Actoxumab and Bezlotoxumab
  • Table 34: Efficacy of Actoxumab and Bezlotoxumab in Terms of CDI Recurrence, Phase II Trial
  • Table 35: Most Common AEs and SAEs Documented After Treatment with Actoxumab and Bezlotoxumab, Phase II Triala
  • Table 36: Actoxumab and Bezlotoxumab SWOT Analysis, 2015
  • Table 37: Product Profile - Cadazolid
  • Table 38: Efficacy Results from Cadazolid Phase II Trial - Modified Intent-to-Treat Populationa
  • Table 39: Cadazolid SWOT Analysis, 2015
  • Table 40: Product Profile - Surotomycin
  • Table 41: Efficacy Results from Surotomycin Phase II Trial - Modified Intent-to-Treat Populationa
  • Table 42: Surotomycin SWOT Analysis, 2015
  • Table 43: Product Profile - SMT19969
  • Table 44: SMT19969 SWOT Analysis, 2015
  • Table 45: Product Profile - SER-109
  • Table 46: SER-109 SWOT Analysis, 2015
  • Table 47: Product Profile - RBX2660
  • Table 48: RBX2660 SWOT Analysis, 2015
  • Table 49: Product Profile - ACAM-CDIFF
  • Table 50: Formulations and Dosing Schedules for ACAM-CDIFF Phase II Trial
  • Table 51: ACAM-CDIFF SWOT Analysis, 2015
  • Table 52: Product Profile - VLA84
  • Table 53: Doses and Dosing Schedules in VLA84 Phase I Trial*
  • Table 54: VLA84 SWOT Analysis, 2015
  • Table 55: Product Profile - PF-06425090
  • Table 56: PF-06425090 SWOT Analysis, 2015
  • Table 57: Innovative Early-Stage Approaches to CDI Prevention and Treatment, 2015
  • Table 58: Phase II Clinical Trial Efficacy Data for LFF571
  • Table 59: Phase II Clinical Trial Safety Data for LFF571
  • Table 60: Efficacy Data from Phase II Clinical Trial of VP20621
  • Table 61: Safety Data from Phase II Clinical Trial of VP20621
  • Table 62: Other CDI Products in Development, 2015
  • Table 63: Clinical Benchmarking of Key CDI Therapeutic Agents, 2015
  • Table 64: Clinical Benchmarking of Key CDI Pipeline Prophylactic Agents, 2015
  • Table 65: Commercial Benchmarking of Key CDI Therapeutic Agents, 2015
  • Table 66: Commercial Benchmarking of Key CDI Pipeline Prophylactic Agents, 2015
  • Table 67: Top-Line Global Sales Forecasts for CDI Therapeutic and Prophylactic Agents, 2014-2024*
  • Table 68: Key Events Impacting Sales from CDI Therapeutics and Prophylactics, 2014-2024
  • Table 69: Global CDI Products Market - Drivers and Barriers, 2014-2024
  • Table 70: CDI Patient Population Segmentations in the 7MM - Secondary Sources Leveraged
  • Table 71: Patient Populations Targeted by CDI Marketed and Pipeline Product Developers
  • Table 72: CDI Marketed and Pipeline Products Broken Down by Therapeutic Class
  • Table 73: Key Pipeline Product Projected Launch Dates by Region
  • Table 74: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Examples of C. difficile-Associated Diseases
  • Figure 2: Overview of the Pathogenesis of CDAD
  • Figure 3: Top-Level Overview of International Treatment Algorithm for CDI and CDAD
  • Figure 4: Incidence Rate for CDI in the 7MM, 2014
  • Figure 5: Case Flow Map for the US
  • Figure 6: Case Flow Map for the 5EU and Japan
  • Figure 7: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Figure 8: Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014
  • Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014
  • Figure 10: 7MM, Age-Standardized Diagnosed Incidence Rates of All-CDI, 2014
  • Figure 11: 5EU and Japan, Recurrent CDI Cases, Ages ≥18 Years, N, 2014
  • Figure 12: US, Diagnosed Incident Cases of CDI Stratified by Recurrence, Ages ≥18 Years, N, 2014
  • Figure 13: 5EU and Japan, Diagnosed Incident Cases of All-CDI Stratified by Epidemiological Association, Ages ≥18 Years, N, 2014
  • Figure 14: US, Diagnosed Incident Cases of All-CDI by Epidemiological Association, Ages ≥18 Years, N, 2014
  • Figure 15: Current Treatment Options for CDIs
  • Figure 16: Competitive Assessment of Key CDI Therapeutic Agents, 2015
  • Figure 17: Competitive Assessment of Key CDI Pipeline Prophylactic Agents, 2015
  • Figure 18: Global Sales from CDI Therapeutic and Prophylactic Agents by Region, 2014 and 2024*
  • Figure 19: US Sales from CDI Therapeutic Agents, 2014 and 2024*
  • Figure 20: US Sales from CDI Prophylactic Agents, 2014-2024
  • Figure 21: 5EU Sales from CDI Therapeutic Agents, 2014 and 2024*
  • Figure 22: 5EU Sales from CDI Prophylactic Agents, 2014-2024
  • Figure 23: Japan Sales from CDI Therapeutic Agents, 2014 and 2024*
  • Figure 24: Japan Sales from CDI Prophylactic Agents, 2014-2024
Back to Top